COMMISSIONER FOR PATENTS
UNITED STATES PATENT AND TRADEMARK OFFICE
WASHINGTON, D.C. 2023

#6

OSTROLENK FABER GERB & SOFFEN LLP 1180 Avenue of the Americas New York, New York 10036-8403

In re Application of CHARLES, Mark David *et al* U.S. Application No.: 09/890,775 PCT No.: PCT/GB00/00345

Int. Filing Date: 04 February 2000 Priority Date: 06 February 1999 Attorney Docket No.: P/3610-16

For: N2-PHENYLAMIDINE DERIVATIVES

RENEWED

DECISION UNDER

37 CFR 1.47(a)

This decision is in response to applicants' "Renewed Petition Under 37 C.F.R. §1.47(a)" submitted 26 September 2002.

BACKGROUND

On 27 March 2002, a decision dismissing applicants' petition under 37 CFR 1.47(a) was mailed because applicants failed to satisfy item (2).

On 26 September 2002, applicants submitted the instant renewed petition which was accompanied by, *inter alia*, a declaration signed by the nonsigning co-inventors, Mr. Simpson and Mr. Charles, a four-month extension and \$1,440.00 fee, and the surcharge fee of \$130.00 pursuant to 37 CFR .1492(e).

DISCUSSION

Here in the renewed petition, applicants have submitted declarations signed by the nonsigning co-inventors, Mark David Charles and Donald James Simpson. These declarations are in compliance with 37 CFR 1.497(a) and (b). Applicants previously submitted declarations signed by the other five co-inventors.

Accordingly, applicants petition under 37 CFR 1.47(a) is moot.

CONCLUSION

For the reasons above, applicants' renewed petition under 37 CFR 1.47(a) is **DISMISSED** as moot.

Applicants have completed the requirements for acceptance under 35 U.S.C. 371(c). The application has an international filing date of 04 February 2000, under 35 U.S.C. 363, and a 35 U.S.C. 371 date of **26 September 2002**.

This application is being forwarded to the National Stage Processing Division of the Office of PCT Operations for continued processing.

James Thomson Attorney Advisor PCT Legal Office

Tel.: (703) 308-6457